News Center

News Center

Dr. Yu Qiang from Shengshi Taikang was interviewed by the First Finance program team for "Science & Innovation Source Power."

Dr. Yu Qiang from Shengshi Taikang was interviewed by the First Finance program team for "Science & Innovation Source Power."

Recently, the team behind "Science & Innovation Source Power," a program jointly presented by First Finance and WeBank, visited Suzhou and delved into the Suzhou Industrial Park. Joining them were Yang Yudong, Editor-in-Chief of First Finance; Wang Qiangbin, Executive Deputy Director of the Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences; Li Wei, Deputy Director of the Institute of Applied Economics at the Shanghai Academy of Social Sciences; Fei Jianjiang, Managing Partner and General Manager of Suzhou Industrial Zone Yuanhe Origin Venture Capital Co., Ltd.; and Yuan Weijia, Deputy General Manager of Corporate Finance at WeBank. Together, they explored the path to upgrading "Made in Suzhou" and thoroughly analyzed the driving forces behind the rapid growth of Suzhou's science and technology enterprises.

Time：2021-12-20 09:07

"Guangming Daily," Front Page – A Report Card from Open Innovation

"Guangming Daily," Front Page – A Report Card from Open Innovation

Located in eastern Jiangsu Province, Suzhou Industrial Park spans 278 square kilometers—every inch of this land brimming with immense potential and dynamic energy. Despite the significant impact of the COVID-19 pandemic, the park achieved a regional GDP of over 129 billion yuan in the first half of the year, representing a robust 2.1% year-on-year growth. Meanwhile, total import and export value surged to more than 305.2 billion yuan, up by 4.5%; registered foreign investment reached $2.07 billion, while actual utilized foreign capital hit $1.28 billion—surging by 149% and 196%, respectively. These impressive results are nothing short of remarkable. But what makes Suzhou Industrial Park stand out? The answer is both simple and profound: **openness and innovation.** As the primary hub for openness and innovation in Suzhou, the park has consistently maintained a forward-leaning, pioneering spirit. It fearlessly pushes boundaries, seizes opportunities with precision, and ultimately places open innovation at the heart of its strategy. This approach may very well be the "secret formula" that keeps the park thriving—even amid complex and ever-changing global circumstances—and it’s undoubtedly its most powerful "trump card."

Time：2020-08-14 09:16

Shengshi Taikang: The Molecular Designer and Their Business Vision

Shengshi Taikang: The Molecular Designer and Their Business Vision

In 2006, Merck’s sitagliptin was officially launched for diabetes treatment, becoming the world’s first approved DPP4 inhibitor. At the time, Yu Qiang, co-founder and CEO of Shengshi Taikang, was running a U.S.-based company focused on applying fragment-based drug discovery technology to deliver drug precursor compounds. After sitagliptin hit the market, Yu Qiang noticed that the compound still had room for improvement in terms of its fit with the target enzyme DPP4. Driven by this insight, his company synthesized numerous compounds targeting the same DPP4 pathway—and subsequently compared them against the publicly available data on sitagliptin. Ultimately, these new compounds demonstrated comparable efficacy to sitagliptin, prompting Yu Qiang to realize that this approach might be heading in the right direction, offering clear opportunities for further optimization.

Time：2020-07-20 09:21

Shengshi Taikang: Tafamidis Marketing Application Accepted by NMPA

Shengshi Taikang: Tafamidis Marketing Application Accepted by NMPA

Every year, the last day of February marks "International Rare Disease Day." Today, more than 7,000 rare diseases are known worldwide, with 80% having genetic origins. Yet only a few dozen of these conditions can currently be effectively treated or managed with medication. Diagnosing rare diseases remains challenging, and the cost of life-saving treatments is often prohibitively high, leaving patients struggling to survive. At the forefront of rare disease research and development, Shengshi Taikang is dedicated to delivering cutting-edge therapeutic solutions that offer new hope to those battling these debilitating conditions. On this special day, Shengshi Taikang proudly announces that its pioneering oral drug, teriflunomide—developed specifically for treating multiple sclerosis (MS), a rare and chronic autoimmune disorder—has officially received acceptance from China’s National Medical Products Administration for its marketing application.

Time：2020-02-29 08:54

[Ranking] Cyzone 2019 Top 50 Innovative Healthcare and Wellness Companies in China Unveiled—Growing and Innovating Against the Grain Amidst the Capital Winter

[Ranking] Cyzone 2019 Top 50 Innovative Healthcare and Wellness Companies in China Unveiled—Growing and Innovating Against the Grain Amidst the Capital Winter

“The valuation bubble in the healthcare and wellness sector is gradually being deflated, as the market returns to rationality.” When asked about the biggest shift in China’s healthcare and wellness venture capital landscape in recent years, several investors highlighted this very point. They noted that after the investment and IPO boom in the healthcare and wellness industry from 2015 to 2017, the sector is now entering a major reshuffling phase. Both startups and investment firms alike will face a process of survival of the fittest, with the Matthew effect intensifying. Ultimately, only the leading companies and institutions will thrive—and even grow stronger over time.

Time：2019-09-19 09:39

What makes the promising new diabetes drug, senglutide—poised to become the best-in-class—so exceptional?

What makes the promising new diabetes drug, senglutide—poised to become the best-in-class—so exceptional?

Last month, Shengshi Taikang Biopharmaceutical Technology (Suzhou) Co., Ltd. announced the completion of its Pre-A round of financing, revealing that its flagship product, Shengetlin, is poised to become a best-in-class drug in its category. Shengetlin is a novel antidiabetic medication belonging to the class of DPP-4 inhibitors—glucagon-like peptide-1 (GLP-1) receptor agonists. Since Merck introduced sitagliptin, the world’s first DPP-4 inhibitor, to the U.S. market in 2006, DPP-4 has rapidly emerged as one of the most promising targets in diabetes drug development. Over the past few years, several top-10 global pharmaceutical companies have successfully developed multiple next-generation DPP-4 inhibitors, each offering improved efficacy, formulation options, and reduced side effects compared to sitagliptin.

Time：2019-08-23 09:53

Focus on the STAR Market: A Survey of Sci-Tech Enterprises in Suzhou Industrial Park—Some Are Charging Ahead, While Others Remain on the Fences

Focus on the STAR Market: A Survey of Sci-Tech Enterprises in Suzhou Industrial Park—Some Are Charging Ahead, While Others Remain on the Fences

Since its launch, the STAR Market has received applications from a total of 65 companies, including five from Suzhou Industrial Park—among them Jiangsu Beiren Robot System Co., Ltd., one of the first batch accepted on March 22, as well as Hejian Chip Manufacturing (Suzhou) Co., Ltd. Additionally, Borei Pharmaceutical, affectionately known as "B Village," recently submitted its listing application. A reporter from First Finance recently visited Suzhou Industrial Park to get an inside look at these innovative enterprises and share their insights with you, dear readers.

Time：2019-04-12 09:56

The "2018 Top 100 Future Healthcare Companies" list by Arterial Network has been officially released, and Shengshi Taikang is proudly featured on the list.

The "2018 Top 100 Future Healthcare Companies" list by Arterial Network has been officially released, and Shengshi Taikang is proudly featured on the list.

From December 18 to 19, 2018, the Arterial Network "2018 Top 100 Future Healthcare" Forum was grandly held at the Ritz-Carlton Hotel in Beijing. Over 2,500 health and medical industry leaders from home and abroad attended the prestigious event.

Time：2018-12-20 10:07

< 123 >
中企跨境-全域组件 制作前进入CSS配置样式

在线客服添加返回顶部

页面顺滑的滚动

屏蔽页面上图片的alt/title提示

右侧在线客服样式 1,2,3 2

图片alt标题设置： Fland Environmental

表单验证提示文本： The content cannot be empty!

循环体没有内容时： Content is being organized—please wait!

CSS / JS 文件放置地